| Prev Close | 2.24 |
| Open | 2.24 |
| Day Low/High | 2.14 / 2.25 |
| 52 Wk Low/High | 1.35 / 4.57 |
| Volume | 56.59K |
| Avg Volume | 457.80K |
| Exchange | NASDAQ |
| Shares Outstanding | 20.85M |
| Market Cap | 46.23M |
| EPS | -0.60 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Company dedicated to meeting the need for critical, hard-to-find medications with ease of access
Imprimis is dispensing preservative-free compounded dorzolamide and dorzolamide/timolol nationwide
Current Growth Expected to Continue in 2018 for the Leading Ophthalmic-Focused Compounding Business in the US
Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.
Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.
These under-$10 stocks look poised to break out and trade higher from current levels.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
TheStreet highlights 3 stocks pushing the Drugs industry lower today.
An epic month of biotech stock performance ends with a significant sell off.
Few firms are positioned to take advantage of a custom Rx trend, but Imprimis has a helpful partner.
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Imprimis Pharmaceuticals, Inc.
Upgrades: ALJ, APWC, EXH, GTN.A, HCOM, LIWA, MOBI, OSTK, SWFT, TMS, VOC Downgrades: ACU, ADK, AXR, BRP, BXE, CAP, CITZ, CLMS, CRWN, CTIB, CVTI, DAVE, DYNT, EDGW, EMMS, ESTE, HTCO, IRIX, LMIA, LNBB, MASC, MCBI, MHH, MOC, NBBC, NOVB, NWPX, PMBC, PNRG, PZZI, RBCAA, RCKY, STRN, SYNL, TOWR, TWIN, UBCP, UMPQ, USAP, WLFC Initiations: AQ, IMMY Read on to get TheStreet Quant Ratings' detailed report:
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
